In 2014 synlab services GmbH purchased INTERLAB GmbH central lab services – worldwide (INTERLAB). In September, INTERLAB merged with synlab Umweltinstitut GmbH, and consequently all documentation carries the synlab logo and will refer to the synlab pharma institute, Munich location, a division of synlab Umweltinstitut GmbH.
Please note that Dr. Hermann Schulz, Chief Executive Officer of INTERLAB until August 31st, 2015, will continue as a Legal Representative (“Prokurist”) of synlab Umweltinstitut GmbH. He will also head the synlab pharma institute as its Executive Vice President.
INTERLAB and synlab have been successfully cooperating since 2004. Hence, no impact on the day to day business or on the handling of study samples is to be expected. Our address, shipping logistics, and contractual terms shall not undergo any modifications. Although email addresses will switch form name@interlab.de to name@synlab.com your messages will automatically be re-routed.
As the new contractual partner, synlab Umweltinstitut GmbH shall overtake all duties and responsibilities of INTERLAB. Although invoices will be issued by synlab Umweltinstitut GmbH (using their tax ID: DE 195 993 312) the bank account at Deutsche Bank AG MuÌnchen will remain unchanged by the moment.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.